Altimmune, Inc. (ALT)
NASDAQ: ALT · IEX Real-Time Price · USD
6.74
-0.46 (-6.39%)
At close: Jul 2, 2024, 4:00 PM
6.83
+0.09 (1.34%)
After-hours: Jul 2, 2024, 7:59 PM EDT
Altimmune Revenue
Altimmune had revenue of $410.00K in the twelve months ending March 31, 2024, down -618.99% year-over-year. Revenue in the quarter ending March 31, 2024 was $5.00K, a -76.19% decrease year-over-year. In the year 2023, Altimmune had annual revenue of $426.00K, a decrease of -726.47%.
Revenue (ttm)
$410.00K
Revenue Growth
-618.99%
P/S Ratio
1,165.56
Revenue / Employee
$6,949
Employees
59
Market Cap
477.88M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 426.00K | 494.00K | -726.47% |
Dec 31, 2022 | -68.00K | -4.48M | -101.54% |
Dec 31, 2021 | 4.41M | -3.78M | -46.12% |
Dec 31, 2020 | 8.19M | 2.38M | 41.09% |
Dec 31, 2019 | 5.80M | -4.53M | -43.85% |
Dec 31, 2018 | 10.33M | -407.15K | -3.79% |
Dec 31, 2017 | 10.74M | 7.50M | 231.82% |
Dec 31, 2016 | 3.24M | -7.40M | -69.59% |
Dec 31, 2015 | 10.64M | 450.46K | 4.42% |
Dec 31, 2014 | 10.19M | -7.72M | -43.11% |
Dec 31, 2013 | 17.91M | -7.26M | -28.85% |
Dec 31, 2012 | 25.18M | 909.61K | 3.75% |
Dec 31, 2011 | 24.27M | 3.27M | 15.59% |
Dec 31, 2010 | 20.99M | -6.56M | -23.80% |
Dec 31, 2009 | 27.55M | -5.36M | -16.29% |
Dec 31, 2008 | 32.91M | 18.27M | 124.75% |
Dec 31, 2007 | 14.64M | 12.98M | 780.39% |
Dec 31, 2006 | 1.66M | 1.08M | 183.80% |
Dec 31, 2005 | 586.07K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Aveanna Healthcare Holdings | 1.92B |
Cross Country Healthcare | 1.78B |
Sharecare | 419.82M |
ZimVie | 350.20M |
Valneva SE | 166.26M |
PureTech Health | 3.33M |
Oculis Holding AG | 995.46K |
ALT News
- 2 hours ago - Levi & Korsinsky Reminds Altimmune, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 5, 2024 – ALT - Accesswire
- 2 hours ago - July 5, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ALT - Accesswire
- 2 hours ago - ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit - PRNewsWire
- 12 hours ago - Altimmune, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm - GlobeNewsWire
- 13 hours ago - Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune Lawsuit – ALT - GlobeNewsWire
- 15 hours ago - Altimmune, Inc. Class Action: Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 5, 2024 - ALT - Accesswire
- 15 hours ago - ALT LAWSUIT ALERT: Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Accesswire
- 15 hours ago - SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT - PRNewsWire